Synaptics Inc. (Nasdaq:SYNA) a leading developer of human interface solutions for mobile computing, communications, and entertainment devices, reported financial results for its second fiscal quarter ended December 31, 2010. Net revenue for the second quarter of fiscal 2011 was a record $159.6 million, an increase of 20% compared with $133.3 million for the comparable quarter last year. Net income for the second quarter of fiscal 2011 was $17.7 million, or $0.50 per diluted share, compared with net income of $12.2 million, or $0.35 per diluted share, for the comparable quarter last year.

Synaptics Incorporated develops and supplies custom-designed human interface solutions that enable people to interact with various mobile computing, communications, entertainment, and other electronic devices.

*******************************************

Power3 Medical Products, Inc. (OTC.BB:PWRM) a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, announced that company management believes it is making great progress in its focus on the development, sales, and marketing of its proprietary innovate diagnostic tests for breast cancer, pancreatic cancer, ovarian cancer, colon cancer, and certain neurodegenerative diseases, such as Alzheimer's and Parkinson's, to name a few.

In addition, Power3 is a party to several litigation matters, most of which relate to various toxic debt instruments that were entered into by Power3 several years ago when it operated under the tenure of Chairman and CEO, Steven B. Rash. Because current management believes these toxic debt instruments are responsible for Power3's depressed stock price and have distracted the company from its mission, Power3 plans to settle as many of these nagging lawsuits as possible prior to the completion of its merger with Rozetta-Cell Life Sciences, Inc. As for those lawsuits that cannot be speedily resolved, Power3 will continue to rigorously defend its position. For example, one such lawsuit involves Neogenomics, Inc., which was recently granted a motion for summary judgment with respect to an amount due under a convertible debenture. Power3 intends to appeal this decision.

Rozetta-Cell Life Sciences, Inc. is a medical biotechnology company that focuses on the delivery and imaging of stem cells during therapy. Power3 plans to effect the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into Power3, with Power3 remaining as the surviving company. The acquisition of Rozetta-Cell is expected to be completed in February 2011.

Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig's disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro®, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer's, Parkinson's, and ALS diseases, for which it is currently engaged in Phase II clinical trials.

*******************************************

American Video Teleconferencing Corp. (PINK: AVOT) is pleased to announce that Wayne Lockhart, BSc. Geology, has joined the company as special geological advisor to AVOT for advancing the company's exploration programs on its newly acquired rare earth property in Quebec.

Mr. Lockhart has over 35 years experience in the mining business having worked for Falconbridge and Phelps Dodge in eastern Canada, Anglo American Corp.(DeBeers) in Africa and Benguet Cons. in the Philippines. Mr. Lockhart in addition to being a lecturer at the University of New Brunswick in Geology, has developed programs for the United Nations (UNDP). Mr. Lockhart is an Honorary Director of the Prospector and Developers Association of Canada (PDAC), a founding and former member of the Association of Exploration Geochemists and a Member of the Society of Economic Geologists.

The company is looking forward to this new relationship with Mr. Lockhart as he will be able to provide the guidance, expertise and leadership that will be needed moving forward, as he has had many years experience working in the province of Quebec.

The 17 elements that are classified as "rare earth" have become a more vital part of our day-to-day lives. Rare earth metals are the life blood of modern personal computers, batteries and alternative energies. To illustrate, there are nearly ten lbs of the rare earth element, lanthanum, in just about every Toyota Prius engine. Furthermore, rare earth elements are vital to military technologies. As opposed to the name, rare earth metals are not particularly uncommon and can be found in most continents. The US government has made significant steps to increase production of these metals, since they will have a large part in President Obama's overhaul of US energy.

*******************************************

Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg gross sales in the fourth quarter of 2010 were $55.7 million, and $141.4 million for the full year 2010. In addition, fourth quarter shipments of Zanaflex Capsules® (tizanidine hydrochloride) and tablets were $15.8 million in the fourth quarter of 2010 and full year shipments were $57.3 million. Zanaflex gross sales are recognized using a deferred revenue recognition model, and are not yet final. As of December 31, 2010, Acorda expects that cash, cash equivalents and short-term investments will be in excess of $235 million. The final year-end balance will be available in the company’s fourth quarter earnings report.

Acorda Therapeutics, Inc., a biotechnology company, develops therapies for multiple sclerosis, spinal cord injury, and other nervous system disorders.

*******************************************

Life Technologies Corporation (Nasdaq:LIFE) announced it will report its fourth quarter and full year 2010 financial results on Thursday, February 3, 2011, after market close. The company will also hold a conference call on the same day at 4:30 p.m. EST to discuss operating results, as well as future expectations.

Life Technologies Corporation operates as a global biotechnology tools company focused on improving the human condition. Its systems, consumables, and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that better the quality of life.

**************************************************************

********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (PWRM.OB).

Crown Equity Holdings Inc. (CRWE.OB) has received from the company 2,000,000 shares of (144) restricted common stock of American Video Teleconferencing Corp. (AVOT.PK) for 12 months IR Services and 1,000,000 shares of (144) restricted common stock for its IT services.